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Pulmonary arterial hypertension is a progressive, fatal disease characterized by elevated pulmo-
nary arterial pressure 25 mmHg and normal pulmonary capillary wedge pressure 15 mmHg.
Physiological features of pulmonary arterial hypertension are characterized clinically by the pres-
ence of pre-capillary pulmonary hypertension not caused by other conditions such as lung diseases
or chronic thromboembolic pulmonary hypertension. There are several therapies currently avail-
able that have been shown to improve hemodynamics and improve outcomes in patients with
pulmonaryarterial hypertension.These therapies include syntheticprostacyclinandprostaglandin
analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Multiple prostacy-
clin and prostaglandin analog formulations are currently in use (both branded and generic), avail-
able for parenteral, inhaled, or oral administration. This review discusses the pharmacology,
clinical effects, and routes of administration of prostacyclin and prostaglandin analogs, empha-
sizing the advantages and disadvantages of each from the clinical perspective.
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Pulmonary hypertension is characterized by hemodynamic
criteria of elevated mean pulmonary arterial pressure
(mPAP) 25 mmHg. Pulmonary arterial hypertension (PAH)
(Diagnostic Group I) is defined by an elevated mPAP
25 mmHg and normal pulmonary capillary wedge pressure
of 15 mmHg.1 Other causes of pulmonary hypertension
such as parenchymal lung diseases, sleep disorders, and
chronic thromboembolic disease must be excluded before
PAH diagnosis can be made.2,3 PAH is a progressive disorder
that leads to right ventricular failure and death.4,5 The
median survival in patients with untreated PAH in the 1990s
was 2.8 years.6 However, recent data suggest that 1-year
survival in patients with PAH (both treated and untreated)
enrolled in prospective registries ranges from 88% to 91%.7,8
This increase in survival may be due, in part, to improved
recognition of the presence of PAH or a greater availability
of drugs to treat this condition.
The 4th World Symposium on pulmonary hypertension
classified PAH as idiopathic, heritable (formerly familial)
including germline mutations in a number of genes and
familial cases with or without identified germline muta-
tions, drug- and toxin-induced, persistent pulmonary
hypertension of the newborn, and the subcategories clas-
sified under PAH associated with other conditions, ie,
connective tissue diseases, human immunodeficiency virus
infection, portopulmonary hypertension, congenital heart
disease, schistosomiasis, or chronic hemolytic anemia as
Group 1 pulmonary hypertension, and pulmonary veno-
occlusive disease and/or pulmonary capillary hemangio-
matosis as Group 1’ pulmonary hypertension.9 Criteria used
to stratify patients with PAH include the 6-minute walk test
distance (6MWD) and World Health Organization (WHO)
functional class (I through IV). Patients with functional class
I are essentially asymptomatic, and patients with functional
class IV exhibit signs of right heart failure and experience
shortness of breath, fatigue (even at rest), and syncope.10Evidence suggests that endogenous prostacyclin, which is
produced by endothelial cells of blood vessels, is decreased
in patients with PAH.7,8 Four prostanoid receptors in the lung
have been identified to be involved in regulating vascular
tone, platelet activation, and immunological cell responses
(for an in-depth review, please see KK Mubarak, 201011).
Thus, synthetic prostaglandin I2 (PGI2), also referred to as
prostacyclin, and prostaglandin analogs are a logical choice
for the treatment of this disease, and current guidelines
recommend their use in patients with functional class IIeIV
PAH.12 Endothelin receptor antagonists and phosphodies-
terase type-5 inhibitors are also used as treatment for
patients with PAH.12 In addition, sequential combination
therapy with these agents should be considered if adequate
response with monotherapy is not achieved or if patients
deteriorate with monotherapy.12 However, data supporting
the use of combination therapy are limited, and such ther-
apies are the focus of current research.13
Prostacyclin and prostaglandin analogs have been used
in routine clinical practice since the 1990s, although there
are reports of the investigational use of prostacyclin in
patients with PAH dating back to the 1980s.14,15 Currently,
there are several different prostacyclin and prostaglandin
analog formulations available (for intravenous [IV] use, as
a subcutaneous [SC] injection, and for inhalation) in the
United States.16 This review discusses the use of prostacy-
clin and prostaglandin analogs (both branded and generic)
to treat patients with Group 1 PAH, with an emphasis on the
advantages and disadvantages of the different routes of
administration used for these agents.
Parenteral prostacyclin and prostaglandin
analogs
Epoprostenol
Epoprostenol, also known as synthetic PGI2 or prostacyclin,
was the first therapy approved by the United States Food
820 Z. Safdarand Drug Administration (FDA) for the treatment of PAH in
1995.17,18 Derived from the metabolism of arachidonic acid,
it is a potent pulmonary and systemic vasodilator, an
inhibitor of platelet aggregation,18,19 and it may modulate
pulmonary vascular remodeling.20
Epoprostenol sodium, which is formulated for IV injec-
tion, is available as Flolan (GlaxoSmithKline, Research
Triangle Park, NC),19 Veletri (Actelion Pharmaceuticals US,
Inc., South San Francisco, CA), and a generic formulation
(Teva Parenteral Medicines, Inc., Irvine, CA).21 The phar-
macological and clinical properties of the active ingredient
(epoprostenol sodium) are identical. Veletri (epoprostenol
sodium for injection) is formulated with extended stability;
however, the clinical indication of this compound is identical
to that of Flolan.22,23 For the purposes of this article, the
brand names Flolan, Veletri, and the generic formulation
epoprostenol sodium for injection will be referred to as
epoprostenol sodium for injection, epoprostenol with
extended stability, and generic epoprostenol sodium for
injection, respectively. The term epoprostenol will be used
to indicate properties that refer to all 3 drugs.
Pharmacological properties
The systemic half-life (t1/2) of epoprostenol is 2e3 min.
Epoprostenol metabolism in humans results in 2 major and
14 minor metabolites, which are excreted primarily via the
kidneys.19,21,22,24 Epoprostenol with extended stability is
more stable upon reconstitution and administration than
branded or generic epoprostenol sodium for injection due
to the use of a buffer that lacks sodium chloride, substi-
tutes arginine for glycine, and has a higher pH.19,21,22,25,26
In addition, epoprostenol with extended stability can be
diluted for delivery with Sterile Water for Injection or
Sodium Chloride 0.9% for Injection, whereas branded and
generic epoprostenol sodium for injection require a special
diluent.25 Additional pharmacological properties of epo-
prostenol are summarized in Table 1.
Clinical effects
Clinical studies in patients with PAH have shown that IV
epoprostenol treatment improves hemodynamic parame-
ters, significantly improves symptoms of dyspnea and
fatigue, and increases exercise capacity (6MWD).19,24,27e33
Significant dose-dependent decreases in several hemody-
namic parameters, including total pulmonary resistance,
pulmonary vascular resistance (PVR), and mPAP, and
increases in cardiac index and stroke volume were observed
with IV epoprostenol therapy.19,24,29 The hemodynamic
effects of epoprostenol are similar in acute and chronic
settings.19,22,24 In addition, IV epoprostenol has been shown
to improve survival and is the only PAH medication to have
an indication for improved survival in its prescribing infor-
mation.19,21,29 However, in patients with PAH due to the
scleroderma spectrum of diseases, no significant improve-
ment in survival was observed with epoprostenol therapy
relative to conventional therapy.28
Adverse events attributable to chronic epoprostenol
administration include headache, flushing, jaw pain,
anxiety/nervousness, diarrhea, flu-like symptoms, nausea,
and vomiting.19,21,22,24 Patients who receive epoprostenol
may also experience adverse events related to the route of
administration.19,21,22,24 Finally, the short systemic t1/2 ofepoprostenol has considerable disadvantages due to the
potential for rebound pulmonary hypertension, cardiovas-
cular compromise, and death in the event of a brief inter-
ruption of IV administration.29,34
Administration
Because of its short systemic t1/2, epoprostenol must be
administered by continuous IV infusion. The drug is
administered through a central venous catheter and by the
use of an ambulatory infusion pump.19,21,22,24 Branded and
generic epoprostenol sodium for injection can be adminis-
tered at room temperature for a maximum of 8 h, which
can be accomplished by using smaller pump cassettes;
however, if the drug is to be administered over 24 h, it must
be kept cold via use of a cold pouch that should be replaced
every 12 h depending on the ambient temperature.19,21
Epoprostenol with extended stability, when diluted
completely and administered immediately, can be infused
at room temperature for up to 24 h at concentrations
ranging from 6000 ng/mL to <30,000 ng/mL without the
use of a cold pouch or ice packs.22,23
There are several important considerations in the
administration of epoprostenol. Long-term administration
requires a permanent indwelling catheter and a continuous
infusion pump, which increases the risks for infection and
thrombosis. Adverse events may be associated with infusion
system malfunctions and subsequent over- or underdosing
of the drug,35 and patients receiving the IV drug can
experience bloodstream infections and sepsis. In addition,
considerable patient education and instruction are required
for the care and maintenance of the catheter and pump,
both of which necessitate sterile techniques.16
The 3 different epoprostenols each come in slightly
different sizes and packaging, and each requires different
storage conditions (Table 1). Branded epoprostenol sodium
for injection is supplied in powder form in 17 mL glass vials.
Two different quantities are available: 0.5 mg (blue cap)
and 1.5 mg (red cap). The lyophilized powder can be stored
at room temperature.19 The drug must be reconstituted
using a specific sterile diluent (Flolan Sterile Diluent for
Injection), which is also stored at room temperature. The
reconstituted solution can be stored at 2e8 C for
a maximum of 48 h before use due to the unstable nature of
the reconstituted soluble compound.
Generic epoprostenol sodium for injection is supplied in
powder form in 10 mL glass vials. Two different quantities
are available: 0.5 mg (blue cap) and 1.5 mg (red cap).21 The
storage conditions of the lyophilized powder, the recon-
stituted solution, and the diluent (Flolan Sterile Diluent
for Injection) are identical to those indicated for branded
epoprostenol sodium for injection.
Epoprostenol with extended stability is supplied in
powder form in 10 mL glass vials of 1.5 mg quantity (red
cap). Unlike branded and generic epoprostenol sodium for
injection, epoprostenol with extended stability can be
reconstituted using either Sterile Water for Injection or
Sodium Chloride 0.9% for Injection.22,23 The lyophilized
powder can be stored at room temperature. When diluted
completely and administered immediately at concentra-
tions ranging from 6000 ng/mL to <30,000 ng/mL, epo-
prostenol with extended stability can be infused for 24 h at
room temperature without the use of ice packs. When
Table 1 Properties and storage conditions of parenteral epoprostenol and treprostinil.
Drug Pharmacological
properties
Vial size Concentrations Diluent Stability
Epoprostenol
sodium for
injection (Flolan)19
Clearancea: 93 mL/kg/min
Volume of distributiona:
357 mL/kg
t1/2
a: 2.7 min
Drug: 17 mL
Diluent: 50 mL
0.5 mg, blue cap
1.5 mg, red cap
Flolan
Diluent: 94 mg gly e;
73.3 mg NaCl; NaO
(to adjust for pH); nd
Sterile Water for I ection
Protect from light
Reconstituted: up to 8 h at RT; >8 h
requires cold pack refrigeration
Generic epoprostenol
sodium for injection21
As above Drug: 10 mL
Diluent: 50 mL
0.5 mg, blue cap
1.5 mg, red cap
As above Protect from light
Reconstituted: up to 8 h at RT; >8 h
requires cold pack refrigeration
Epoprostenol with
extended stability
(Veletri)24
As above Drug: 10 mL
Diluent: 50 mL
1.5 mg, red cap Sterile Water for I ection,
or Sodium Chloride .9%
for Injection
Protect from light
Reconstituted 6000 ng/mL and
<30,000 ng/mL: can be administered
immediately over 24 h at RT
Reconstituted 30,000 ng/mL: can be
stored for 7 days at 2e8 C and then
administered over 24 h at RT
IV/SC treprostinil
(Remodulin)37
Clearanceb: w429 mL/kg/h
Volume of distributionb:
w1.4 L/kg
Terminal t1/2: w4 h
Bioavailability:100%
20 mL 1.0 mg/mL, yellow cap
2.5 mg/mL, blue cap
5.0 mg/mL, green cap
10 mg/mL, pink cap
5.3 mg NaCl;
3.0 mg metacresol
6.3 mg Na citrate;
H2O
IV: up to 48 h at 37 C
SC: up to 72 h at 37 C
H2O, water; IV, intravenous; Na, sodium; NaCl, sodium chloride; NaOH, sodium hydroxide; RT, room temperature; SC, subcutaneo ; t1/2, half-life.
a In animals.
b For a person with an ideal body weight of 70 kg.
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822 Z. Safdardiluted to concentrations 30,000 ng/mL, epoprostenol
with extended stability can be stored for up to 7 days at
2e8 C and then infused for 24 h at room temperature
without the use of ice packs.22,23
Treprostinil
Treprostinil is a prostaglandin analog that is stable at room
temperature and has a neutral pH.36,37 Similar to epopros-
tenol, treprostinil is a potent pulmonary and systemic
vasodilator and an inhibitor of platelet aggregation.36e38
Parenteral treprostinil is available as a branded product
only (Remodulin; United Therapeutics Corp., Research
Triangle Park, NC).37 The manufacturer recommends that
treprostinil be administered via a continuous SC infusion,
with IV infusion used only in the event of intolerance to SC
administration (eg, severe injection site pain/reactions).37
Pharmacological properties
The pharmacological properties of treprostinil are summa-
rized in Table 1. It is metabolized by the liver into 5
metabolites, which are primarily excreted in the urine.
Treprostinil has linear pharmacokinetics over the dose
range of 1.25e125 ng/kg/min.37
Clinical effects
Treatment of patients with PAH with IV or SC treprostinil
improves hemodynamic parameters and exercise capaci-
ty.39e44 The effects of treprostinil on hemodynamics have
been mixed: some studies show significant improvement in
hemodynamics compared to baseline or placebo,39,42e44
whereas others do not.41 In a study comparing IV trepros-
tinil with epoprostenol, the hemodynamic changes were
similar for both of these agents.41 A study in healthy
volunteers showed that IV and SC treprostinil were bio-
equivalent.45 In animal studies, the use of treprostinil
reduced ventricular afterload (both right and left) and
increased stroke volume and cardiac output.37
The most frequent adverse events associated with
chronic SC treprostinil administration are infusion site pain,
infusion site reactions, and bleeding.5,37 Other prostacy-
clin-related adverse events include headache, diarrhea,
nausea, jaw pain, and vasodilation. Adverse events asso-
ciated with infusion system malfunctions include over- or
underdosing of treprostinil, and patients receiving IV tre-
prostinil can experience bloodstream infections and
sepsis.37 The increased risk of infections associated with
treprostinil may be due to its receptor affinity; unlike other
prostaglandin analogs, in in vitro studies and animals, tre-
prostinil modulates T lymphocyte and dendritic cell func-
tions in an IP receptor-independent fashion and may affect
endogenous immune function.46,47 Recent preliminary
results of an observational study suggest that adjusting the
pH of the buffer from neutral to basic by using Flolan
diluent may reduce the incidence of sepsis following
treatment with IV treprostinil.48
Administration
Patients receive SC treprostinil via a self-inserted SC
catheter coupled to an infusion pump. Those receiving IV
treprostinil require a central venous catheter and infusionpump. SC treprostinil requires no dilution before use;
however, IV treprostinil must first be diluted using Sterile
Water for Injection, Sodium Chloride 0.9% for Injection, or
Flolan Sterile Diluent for Injection.37
Treprostinil is supplied as a solution in multi-use, 20 mL
vials. Four different concentrations are available, ranging
from 1 to 10 mg/mL (Table 1).37 Unopened vials of tre-
prostinil can be stored at room temperature. When used
subcutaneously, treprostinil can be administered for up to
72 h at 37 C; however, the diluted solution for IV admin-
istration can only be used for up to 48 h at 37 C.
The basic pH and short systemic t1/2 of epoprostenol
necessitate IV infusion, whereas the neutral pH and longer
systemic t1/2 of treprostinil enable either IV or SC adminis-
tration.5 The longer t1/2 lowers the risk for rebound PAHwith
infusion cessation, and no cases of rebound PAH have been
reported in the medical literature. In addition, because
treprostinil does not require refrigeration, it has the poten-
tial to considerably improve quality of life for these patients.
Inhaled prostaglandin analogs
Inhaled prostaglandin analogsweredeveloped, in part, due to
the limitations of parenteral administration and are often
used as a bridge to IV therapy or lung transplantation. The
adverse event profile is similar to that seen following paren-
teral administration, whereas complications due to contin-
uous parenteral administration are eliminated.5 It is thought
that the incidence of adverse events associated with paren-
teral prostacyclin and prostaglandin analogs (ie, catheter-
induced sepsis or thromboembolism and infusion site pain/
reaction) is obviated with inhaled prostaglandin analogs due
to the direct delivery of the drug to the lung.43,49e51
Inhaled iloprost
Like epoprostenol and treprostinil, inhaled iloprost is
a systemic and pulmonary vasodilator that also has anti-
platelet properties.52 Inhaled iloprost is available as
a mixture of the 4S and 4R stereoisomers; with respect to
vasodilation, the 4S isomer is more potent than the 4R
isomer.53 Iloprost is marketed under the brand name
Ventavis (Actelion Pharmaceuticals US, Inc., South San
Francisco, CA) in the United States.53 There are no generic
versions of inhaled iloprost available. Despite lack of
supportive clinical evidence, an IV formulation of iloprost is
approved for the treatment of PAH in New Zealand and has
been used off-label in a number of countries including
Germany, Switzerland, and Australia.16,54
Pharmacological properties
The systemic t1/2 of inhaled iloprost is 20e30 min; additional
pharmacological properties are summarized in Table 2.
Inhaled iloprost is metabolized via oxidation to produce one
major metabolite, which is excreted primarily in the urine.53
Clinical effects
Inhaled iloprost improves hemodynamic parameters, func-
tional status, andexercise capacity in patientswith PAH.55e62
Furthermore, the addition of inhaled iloprost to stable
ongoing bosentan therapy significantly delayed the time to
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Prostacyclin and prostaglandin analogs in the treatment of PAH 823clinical worsening in a 12-week, randomized, double-blind
trial of 67 patients with PAH.63 Hemodynamic effects of
inhaled iloprost in humans includedecreases in PVRandmPAP
and increases incardiacoutputandoxygen saturationafter12
weeks and 2 years of treatment.58,62 Unlike parenteral epo-
prostenol and treprostinil, the effect of inhaled iloprost on
mean systemic arterial pressure has been variable; some
studies show no effect,61,64e66 whereas others demonstrate
a significant reduction.58 It has also been shown that patients
receiving inhaled iloprost do not experience rebound symp-
toms during the night, which may occur with interruption of
parenteral infusion of epoprostenol or treprostinil.67
Adverse events associatedwith inhaled iloprost are similar
to those seenwith prostacyclin and prostaglandin analogs, ie,
headache, flushing, flu-like symptoms, nausea, and vomiting.
Patients receiving inhaled iloprost can also experience jaw
muscle spasm. Additional adverse events include cough and
tongue pain, and syncope.53,58 Notably, when iloprost was
added to bosentan therapy, syncope was infrequent and less
severe (1 patient) than in an iloprost monotherapy study in
which there were 5 cases of serious syncope.58,63
Administration
Inhaled iloprost should be administered 6e9 times a day as
needed (no more frequently than once every 2 h) during
waking hours using the I-neb Adaptive Aerosol Delivery
(AAD) System (Philips Respironics, Respiratory Drug
Delivery Ltd., Chichester, UK),53 which may be a limitation
for young patients with an active lifestyle. Iloprost for
inhalation is supplied in 1 mL ampules in concentrations of
10 mg/mL (for patients receiving either 2.5 or 5 mg per dose)
and 20 mg/mL (for patients experiencing extended treat-
ment times when maintained on 5 mg iloprost/dose). The
ampules should be stored at room temperature. Properties
of the inhaled iloprost solution are included in Table 2.
Inhaled treprostinil
The inhaled formulation of treprostinil is the most recent
prostaglandin analog to be approved by the US FDA (July
2009).68 It is marketed by United Therapeutics under the
brand name Tyvaso.
Pharmacological properties
Data available for the inhaled formof treprostinil include the
following. A systemic exposure of inhaled treprostinil was
proportional to the administered dose in a single-dose study
in healthy volunteers.68 In one study that included patients
with PAH, 30 mg/dose (4/day) and 45 mg/dose (4/day)
caused a maximum blood concentration of 0.33 ng/mL and
0.96 ng/mL, a time tomaximum concentration of 15 min and
45 min, and a t1/2 of 44 min and 52 min, respectively.
69 A
similar dose proportionality in patients with PAH has been
reported in a second study.70 The bioavailability of inhaled
treprostinil was 64% after administration of 18 mg and 72%
after 36 mg in healthy volunteers (Table 2).
Clinical effects
Clinical studies of inhaled treprostinil havebeenconducted in
patients already receiving theendothelin receptorantagonist
bosentan or the phosphodiesterase type-5 inhibitor sildenafil
824 Z. Safdarand have shown that inhaled treprostinil significantly
improves hemodynamics, functional class, and exercise
capacity when added to oral therapy.68e70 However, in one
study (TRIUMPH-I), inhaled treprostinil significantly improved
exercise capacity (6MWD), but not functional class, when
added to oral therapy.69 Hemodynamic effects of inhaled
treprostinil include decreases in mPAP and PVR.69,70
Adverse events associated with inhaled treprostinil
include cough, headache, pharyngolaryngeal pain and
throat irritation, nausea, flushing, and syncope.68e70
Administration
Inhaled treprostinil should be administered 4 times daily,
4 h apart during waking hours using the Tyvaso Inhalation
System. Patients should be initiated on 18 mg of inhaled
treprostinil (3 mg/breath), which should be increased to
54 mg (9 breaths) within 6 weeks, provided the increased
dose is tolerated.
Inhaled treprostinil is supplied in 2.9 mL ampules at
a concentration of 0.6 mg/mL (Table 2). It should be used
undiluted. Unopened ampules should be stored at room
temperature and protected from light.68
Oral prostaglandin analogs
Oral formulations of prostaglandin analogs are currently in
development for use in theUnited States. An oral formulation
of treprostinil has been developed by United Therapeutics;
however, this formulation has not yet been approved in the
United States and is currently undergoing assessment in
clinical trials.16,71e73 Similarly, beraprost (Procyclin) has
launched in Japan and Korea by Kaken Pharmaceuticals and is
also undergoing assessment in the United States.74e85
Switching between PAH therapies
The challenges of administration and adverse events asso-
ciated with parenteral epoprostenol or treprostinil therapy
(particularly the IV route) occasionally necessitate switch-
ing therapy, either from one analog to another or from
prostaglandin analog therapy to another drug class, such as
endothelin receptor antagonists or phosphodiesterase type-
5 inhibitors.
The literature on switching between prostacyclin and
prostaglandin analogs mainly documents switching from IV
epoprostenol to IV or SC treprostinil86e90; in all of these
studies, switching from epoprostenol to treprostinil was
successful in that it did not cause any clinical deterioration
or change in functional status and generally resulted in an
improvement in treatment-related adverse events.
Evidence for transitioning patients from parenteral to
inhaled therapies is primarily anecdotal with few controlled
studies.88 Practice patterns for transitioning patients vary
greatly from transitioning over a period of weeks, to over
hours, and often with an overlap period.
Although functional tests (eg, 6MWD and Borg dyspnea
index) generally remain the same after transitioning from
epoprostenol to treprostinil,86e90 the effect upon hemody-
namics is more variable; one study reported increases in
mPAP and PVR and a decrease in cardiac index,86 but two
others reported no change in hemodynamics,87,89 andhemodynamics were not reported in two additional
studies.88,90 Despite the potential worsening hemody-
namics, there is little evidence that clinical deterioration
in patients on treprostinil differs from those receiving
epoprostenol.87,88,90
The results of studies investigating the transition of
patients with PAH from prostacyclin or prostaglandin analogs
to oral agents of adifferent classweremixed;while generally
the transitions were successful, some patients did deterio-
rate when switched to oral therapy, and the conclusions
generally called for care when selecting patients suitable for
transition.91e94 Those patients most likely to successfully
transition from parenteral epoprostenol or treprostinil
therapy to bosentan or sildenafil had better hemodynamics
at the time of the transition.92,94 Patients successfully tran-
sitioned may have to go back on parenteral prostacyclin or
prostaglandin analog therapy as their disease progresses.93
However, it may be worth considering transitioning care-
fully selected patients to an oral therapy due to decreased
adverse events reported on transitioned patients.91e94
Conclusions
Administration of prostacyclin and prostaglandin analogs in
patients with PAH requires attention to detail due to
numerous differences among the drugs. These differences
include package size, concentration or dose, route of
administration, ease of use, cost, availability, and admin-
istration device. Thus, the clinician should not only weigh
the pharmacological benefits of prostacyclin and prosta-
glandin analogs when deciding on treatment in patients
with PAH but also whether the patient can comply with drug
storage requirements, route of administration, and use of
the administration device.
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